Clinical Trial Update: Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy [Phase 2]

View source ↗

Summary

A phase 2 clinical trial is evaluating the combination of serplulimab, lenvatinib, and paclitaxel as second-line therapy for advanced gastric adenocarcinoma or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• PACLITAXEL (PACLITAXEL)
• Serplulimab (serplulimab)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: RECRUITING